In the Spotlight...
A minimal gene set characterizes TIL specific for diverse tumor antigens across different cancer types
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies
Small circular RNAs as vaccines for cancer immunotherapy
Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen
Previous Digests
PD-L1 and CD80 interactions make DCs move
February 12, 2025
Research has shown that PD-L1 expression on dendritic cells (DCs) is essential for intracellular signaling that plays a role in chemokine-mediated DC migration. In a recent paper in Science Advances, Kantheti et al. investigated whether the extracellular interaction of...
Cholesterol supports cDC maturation, while AXL dampens in
February 5, 2025
The maturation of dendritic cells plays a critical role in initiating a cascade of immune responses, but exactly how cDCs mature in the absence of inflammation is not entirely understood. Investigating this process, Belabed and Park et al. found...
First glimpses of efficacy of personalized neoantigen vaccine plus checkpoint blockade in advanced cancers
January 29, 2025
Few patients with advanced cancer respond or have durable response to current immunotherapies. One of the challenges is that neoantigen-specific T cell responses only rarely spontaneously arise in many tumors. Therefore, therapies that trigger the induction of neoantigen-specific T...
Watch ACIR in action
In November 2019, ACIR received the Visionary Award from the Cambridge Chamber of Commerce.
Watch the 3-minute video explaining ACIR's mission and goal:
In September 2020, ACIR was featured in the documentary The American Dream on Bloomberg TV.
Watch the 6-minute segment on the story behind your favorite digest here:
About ACIR
ACIR's mission is to fast-track cancer immunotherapy research by helping researchers stay on top of the new literature in this fast-moving and multifaceted field, fostering their creativity and productivity in bringing us ever closer to curing this deadly disease.
Ed Fritsch
Ute Burkhardt
Lauren Hitchings
Gaelle Llambi
Maartje Wouters
Alex Najibi
Katherine J. Turner
Stan Wolf
Paula Hochman
Shishir Pant
Nathan Suek
Morgan Janes
TESTIMONIALS
I am pleased to voice my support for the mission of ACIR to keep cancer immunotherapy researchers up to date with the current advancements in the field. Given the magnitude of new information emerging from this field, I particularly appreciate their efforts to both identify and highlight the key advancements each week and to distill the new information to key take-away points that can be easily grasped.
Professor of Medicine, Harvard Medical School; Director, MGH Center for Cancer Immunology; Institute Member, Broad Institute of Harvard and MIT
Current Sponsors
